VANCOUVER, Dec. 24, 2019 /PRNewswire/ – Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced it has received a Complete Response Letter…Original Article
Correvio Receives Complete Response Letter From U.S. FDA for Brinavess and Provides Update on Recent Events
